Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) for the reporting period of September 1, 2025. The registrant is incorporated in Delaware and its principal executive offices are located in Kuala Lumpur, Malaysia. The filing reports the entry into a material definitive agreement regarding the amendment of existing common stock purchase warrants.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the terms of a securities agreement.
Material Changes
On September 1, 2025, the Company issued amended and restated Series A, B, and C common stock purchase warrants. The primary material change is the removal of the "Ownership Limitation" previously attached to these warrants. Previously, holders could not exercise warrants if it resulted in them holding or voting more than the lower of (i) the maximum percentage allowed under Nasdaq rules without a stockholder vote, or (ii) 4.99% of shares outstanding prior to the original issue date. The Amended Warrants now allow exercise and voting without regard to this limitation.
Warrant Terms
- Series A: 218,000 shares per holder; Exercise Price: $7.65; Expiration: 5 years from issuance.
- Series B: 218,000 shares per holder; Exercise Price: $9.00; Expiration: 5 years from issuance.
- Series C: 218,000 shares per holder; Exercise Price: $10.20; Expiration: 5 years from issuance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general business risks. The removal of the ownership limitation was approved by the Board of Directors and the majority stockholder, with the effective date of the approval being July 28, 2025, as disclosed in a prior Schedule 14C filing.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the potential dilution impact if all Amended Warrants are exercised.
- Review the full text of the Amended Warrants (Exhibits 10.1, 10.2, and 10.3) for any other modified terms not summarized in the 8-K.
- Confirm the current market price of the stock relative to the exercise prices ($7.65, $9.00, and $10.20) to determine if the warrants are currently in-the-money.
- Check the July 7, 2025 Schedule 14C filing for details on the stockholder approval process for the removal of the ownership limitation.